bexarotene has been researched along with Cardiotoxicity in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y; Dvornikov, AV; Ekker, SC; Herrmann, J; Hsiai, TK; Kim, M; Lin, X; Lowerison, M; Ma, X; Norton, N; Qiu, Q; Wang, Y; Wang, Z; Xu, X; Yu, Y; Zhang, H; Zhu, P | 1 |
1 other study(ies) available for bexarotene and Cardiotoxicity
| Article | Year |
|---|---|
Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity.
Topics: Animals; Bexarotene; Cardiotonic Agents; Cardiotoxicity; Disease Models, Animal; Endothelial Cells; Heart; Humans; Isotretinoin; Myocardium; Neoplasms; Pericardium; Retinoid X Receptor alpha; Zebrafish; Zonula Occludens-1 Protein | 2020 |